FAST NEWS: Lepu Biopharma to raise $32 million in share sale

2157.HK
Lepu touts itself as the only biotech company in China working on all three very promising fronts, with PD-1 products in the new drug application (NDA) stage, multiple “smart missile” antibody-drug conjugate (ADC) products in clinical trials, and OV products under development.

The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for a sale price of HK$4.58 per share.

Looking Up: The company expects to receive approximately 230 million yuan ($32 million) in net proceeds from the placement, which it will use for R&D, clinical trials and other workstreams for its antibody-drug conjugates (ADC) and oncolytic virus (OV) products, and to replenish its working capital.

Take Note: The placement share price represents a 13.09% discount to the company’s closing price of HK$5.28 on Thursday.

Digging Deeper: Lepu touts itself as the only biotech company in China working on three very promising fronts, with PD-1 products in the new drug application (NDA) stage, multiple “smart missile” antibody-drug conjugate (ADC) products in clinical trials, and OV products under development. The company made a Hong Kong IPO in 2022 just as medical stocks were falling out of favor, making it settle for a valuation that was 14% below what it got in its post-series-C funding, raising about HK$800 million ($103 million). It recorded 225 million yuan in revenue last year but failed to earn a profit after recording its first sales at the end of 2022.

Market Reaction: Lepu’s shares fell on Friday and were down 6.3% to HK$4.94 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by A. Au

To subscribe to Bamboo Works weekly free newsletter, click here

,
, , ,

Related Articles

RELATED ARTICLES

  1. Genfleet bio
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  2. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  3. NEWS WRAP: Surging Xtalpi seizes on tech rally to raise $267 million
    2228.HK
  4. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Zijin Mining spinning off its overseas gold mining arm and taking it public, in order to benefit from surging gold price

Zijin Mining sees gold in IPO for international arm

The company hopes to take advantage of record gold prices to raise big money from a separate listing for its overseas business mining the precious metal Key Takeaways: Zijin Mining…
2899.HK 601899.SHG

Uber’s Chinese robotaxi romance, and Webull’s strong debut

Uber has signed new alliances with Chinese robotaxi operators Momenta and Pony AI, and fortified an existing partnership with WeRide. Why the sudden embrace of Chinese robotaxis? And Webull's stock has charged from the gate with massive gains following its SPAC listing. What's driving this company, which is an unusual hybrid of a U.S.-based business with strong China ties?
BULL.US